Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Novo Nordisk), semaglutide (Ozempic, Rybelsus
FDA-labeled warnings include: Risk of thyroid C-cell tumors (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2) Pancreatitis (report severe abdominal pain, with or without vomiting) Gallbladder disease (including gallstones and cholecystitis) Acute kidney injury secondary to dehydration from gastrointestinal symptoms Hypoglycemia when used with insulin or insulin secretagogues (dose adjustments may be needed) Diabetic retinopathy complications in patients with type 2 diabetes and pre-existing retinopathy Suicidal behavior and ideation (monitor for depression or suicidal thoughts) Intestinal obstruction/ileus (particularly with severe constipation) These medications are contraindicated during pregnancy and should be discontinued at least two months before a planned pregnancy
Alternatives to Ozempic
Psychological Factors : Addressing emotional health is important as psychological barriers can hinder weight loss efforts
For patients who need semaglutide for obesity or weight management, that's a meaningful addition to the Canadian market
Semaglutide is administered either as a once-weekly subcutaneous injection (Ozempic, Wegovy) or as a daily oral tablet (Rybelsus)
US$ 21.80
US$ 21.31
US$ 28.16
